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Background The prognosis of patients with hepatocellular carcinoma (HCC) 
remains poor, largely due to intrahepatic metastasis (IM). Using a mouse model of IM, 
we investigated whether monocyte chemoattractant protein-1 (CCL2/MCP-1) could 
potentiate the antitumor effects of the herpes simplex virus thymidine kinase/ganciclovir 
(HSV-tk/GCV) system.  
Methods Mouse hepatoma cells infected with recombinant adenovirus vectors 
(rAds) expressing HSV-tk, CCL2/MCP-1, and LacZ at multiplicities of infection 
(MOIs) of Ad-tk/Ad-MCP1 = 3/0.03 (T/MLow), 3/3 (T/MHigh), and Ad-tk/Ad-LacZ = 3/3 
(T/L) were injected into BALB/c mice.  
Results  Intrahepatic tumor growth was significantly lower in T/MLow mice. In 
contrast, no tumor suppression was observed in T/MHigh mice. The tumor-specific 
cytolytic activities of splenocytes from T/MLow and T/MHigh mice were comparable. 
Immunohistochemical analysis of liver tissues showed similar infiltration by Mac-1+ 
and T cells in these animals, whereas the proportions of classical activated (M1) 
monocytes/macrophages were significantly higher in T/MLow mice. In addition, IL-12 








were increased in T/MHigh mice.  
Conclusions Collectively, these results demonstrate that an adequate amount of 
CCL2/MCP-1, together with the HSV-tk/GCV system, may induce Th1-polarized 
antitumor effects without inducing tumor angiogenesis in the microenvironment of 











Primary liver cancer is the fifth most common neoplasm in the world and the 
third most common cause of cancer-related deaths [1, 2]. Despite the development of 
novel modalities for treatment of hepatocellular carcinoma (HCC), including 
transcatheter arterial embolization, percutaneous ablation, surgical resection and liver 
transplantation, the prognosis of patients with HCC still remains relatively poor. One of 
the major factors responsible for these unsatisfactory outcomes is the high frequency of 
intrahepatic recurrence after curative treatment [1, 2]. Intrahepatic recurrence is due to 
two mechanisms; intrahepatic metastasis (IM) originating from the primary cancer, and 
a second primary cancer arising from multicentric carcinogenesis (MC). IM may 
correlate with early recurrence and poor prognosis, whereas MC is associated with 
relatively good prognosis [3-5].  
 
To develop novel antitumor strategies for HCC, we have investigated the 
effectiveness of immune gene therapy using suicide genes and chemokine molecules, 
including chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-1) 








monocytes/macrophages to inflammatory sites and tumor tissues as well as their 
activation, including lysosomal enzyme release and tumoricidal activity, and is 
functional in both mice and humans [9]. Transfectant-derived CCL2/MCP-1 has been 
found to successfully recruit monocytes into tumor tissue [10, 11]. We recently 
described a combination strategy for the treatment of HCC, consisting of the herpes 
simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system and CCL2/MCP-1 
gene delivery. We found that adenovirally delivered CCL2/MCP-1 enhanced the 
antitumor effects of the HSV-tk/GCV system by activating innate immune responses 
involving monocytes/macrophages, as well as demonstrating prolonged efficacy 
mediated by NK cells [6-8]. These experiments were performed in athymic nude mice, 
deficient in acquired immune responses, subcutaneously transplanted with HCC. 
 In this study, we have used a liver metastasis model, in which tumor cells were 
infused through the portal vein (PV), to investigate whether CCL2/MCP-1 gene 
delivery could potentiate the antitumor effects of the suicide gene system. Our results 
indicate that the antitumor effects of the suicide gene are enhanced by codelivery of an 
adequate amount of CCL2/MCP-1. These antitumor effects were associated with the 
recruitment of monocytes/macrophages and T cells, T helper 1 (Th1) cytokine gene 








that CCL2/MCP-1 has an immunomodulatory effect on suicide gene therapy for HCC 









Materials and methods 
 
Animals 
Male BALB/cA Jcl mice, 6-8 weeks of age, were obtained from CLEA Japan Inc. 
(Tokyo, Japan), maintained at constant room temperature (25 °C) and provided with free 
access to standard diet and tap water throughout, according to institutional guidelines. 
 
Cell lines and cell culture 
The mouse HCC cell line BNL 1ME A.7R.1 (BNL) and the mouse colon 
cancer cell line colon 26 clone 20 (CT 26), derived from BALB/c mice (H-2d), were 
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10 % 
heat-inactivated (30 min at 56 °C) fetal bovine serum (FBS), non-essential amino acids, 
sodium pyruvate, HEPES buffer, 2 mM glutamate, 1 mM penicillin/streptomycin and 
0.2 mM gentamicin (Gibco, Long Island, NY) at 37 °C in 5 % CO2. 
 
Recombinant adenovirus vectors 
The following replication-defective adenovirus vectors, driven by the CAG 








the HSV-tk gene; Ad-MCP1, which expresses the human CCL2/MCP-1 gene; and 
Ad-LacZ, which expresses the LacZ gene [13] (Figure 1A). Each recombinant 
adenovirus vector was purified and titered according to protocols supplied by the 
manufacturer (Takara, Ootsu, Japan). Briefly, each gene fragment, i.e. HSV-tk, 
CCL2/MCP-1 and LacZ, was excised from its respective insert-containing pBluescript 
vector and inserted into the cosmid pAxCA-wt (Takara, Ootsu, Japan), which contains 
essentially the full-length adenovirus type 5 genome apart from the E1 and E3 regions, 
thus generating the pAxCA gene (Figure 1A). The rAds were generated by transfecting 
293 cells with pAxCA-gene and adenovirus 5-dIX DNA-terminal protein complex. 
These rAds were propagated in 293 cells [14], and viral stocks were prepared by 
standard protocols [15]. The titers of rAds were determined by the 50 % tissue culture 
infectious dose (TCID50) method [16]. 
 
ELISA for CCL2/MCP-1 
 Aliquots of 2.5×104 BNL cells were seeded in 3.0 ml of culture media in 6-well 
tissue culture plate. After 24 hours, the cells were infected with Ad-MCP1 and 
Ad-MCP1, together with Ad-tk, at various multiplicities of infections (MOIs). After 24 








were determined by ELISA. Briefly, each well of a 96 well microtiter plate (Nalgene, 
Rochester, NY) was coated with 0.05 M carbonate buffer (pH 9.6) containing 
monoclonal anti-human CCL2/MCP-1 antibody (ME 6.1; 1 μg/ml) overnight at 4 °C. 
After washing with phosphate buffered saline (PBS) containing 0.05 % Tween 20 
(PBS-T), the plates were blocked with PBS containing 1 % BSA for 1 hour at 37 °C. 
Diluted culture medium or various concentrations of recombinant CCL2/MCP-1 were 
added to duplicate wells and incubated for 2 hours at 37 °C. The plates were washed, 
incubated with rabbit anti-CCL2/MCP-1 antibodies (1 µg/ml) for 2 hours at 37 °C, 
washed again and incubated with alkaline phosphatase-conjugated goat anti-rabbit 
antibody (1/12,000; Tago, Burlingame, CA) for 2 hours at 37 °C. The plates were 
washed, aliquots of 1 mg/ml p-nitrophenylphosphate (Sigma, St. Louis, MO) in 1 M 
diethanolamine (pH 9.8) supplemented with 0.5 mM MgCl2 were added to the wells, 
and the plates were incubated for 40 min at room temperature. After addition of 1 M 
NaCl, the optical density (405 nm wavelength-OD405) was assessed using an ELISA 











 To evaluate the direct antitumor effect of CCL2/MCP-1, 1×107 BNL cells 
suspended in 0.5 ml of culture medium were infected in vitro with CCL2/MCP-1 at 
various MOIs: 0.03 (MLow), 0.3 (MMod), and 3 (MHigh), Ad-LacZ at an MOI of 3 (L), or 
PBS (-). The cells were harvested after 30 min incubation at 37 °C. BALB/c mice were 
anesthetized by intraperitoneal injection with sodium pentobarbital (Somnopentyl, 
Schering-Plough Animal Health Corporation, Kenilworth, NJ), and laparotomy was 
performed. Each mouse was injected with 1 × 106 adenovirus-infected BNL cells in a 
volume of 0.2 ml PBS containing 2 % FBS or 0.2 ml PBS (-) via PV on day 0. The mice 
were sacrificed on day 21, and their liver tissues were weighed. 
To determine whether CCL2/MCP-1 can enhance the antitumor effects of the 
HSV-tk/GCV system, BNL cells were infected with Ad-tk, Ad-MCP1 and Ad-LacZ at 
various MOIs: Ad-tk/Ad-MCP1 = 3/0.03 (T/MLow), 3/0.3 (T/MMod) and 3/3 (T/MHigh), 
Ad-tk/Ad-LacZ = 3/3 (T/L), and Ad-LacZ = 6 (N/L). BALB/c mice were anesthetized 
and each was injected via portal vein with 1 × 106 adenovirus-infected BNL cells on day 
0, followed by intraperitoneal injection of 75 mg/kg/day ganciclovir on days 2-6. The 
mice were sacrificed on day 21, and the livers were removed and weighted. Additionally, 
in another series of experience, the livers removed from the mice on days 1, 3, 7 and 14 








Simultaneously, their splenocytes were tested for cytolytic activity against 51Cr-labeled 
BNL cells. 
 
Histopathological and immunohistochemical analysis 
 Liver sections were fixed in 10 % zinc-buffered formalin and stained with 
hematoxylin and eosin (H-E). For histological evaluation, mouse livers were harvested, 
embedded in tissue-Tek® OCT embedding medium (Sakura Finetek, Torrance, CA) and 
stored at -80 °C until use, except those stained for CD31 (Abcam, Cambridge, MA), 
arginase I (Arg-I; BD Biosciences, Franklin Lakes, NJ) and inducible nitric oxide 
synthase (iNOS; Thermo Fisher Scientific, Fremont, CA). Cryostat sections of frozen 
tissues were fixed in cold acetone for 10 minutes and rinsed three times with PBS. The 
tissue samples used for CD31, iNOS and Arg-I staining were fixed in 10 % 
phosphate-buffered formalin and embedded in paraffin. Following blocking of 
nonspecific tissue avidin and biotin with a blocking kit (Vector Laboratories, 
Burlingame, CA), the slides were incubated with biotin-conjugated monoclonal 
antibody against Mac-1 (CD11b), CD4, CD8 (PharMingen, San Jose, CA) or Arg-I or 
polyclonal antiserum against CD31 or iNOS for 30 minutes at room temperature. 








visualized using a Vectastain® ABC Standard Kit (Vector Laboratories, Burlingame, 
CA), followed by counterstaining with hematoxylin. 
 
Real-time quantitative RT-PCR 
The Frozen liver specimens containing necrotic liver tissues or tumor tissues 
were broken into fine pieces and total RNA was extracted from liver tissues using a 
ToTALLY RNA® kit (Ambion, Austin, TX) according to the manufacturer’s protocol. 
Total RNA (1 μg) was reverse transcribed into cDNA using a SuperScript® first-strand 
synthesis system for RT-PCR (Invitrogen, Carlsbad, CA). The first strand cDNA was 
used for real-time quantitative PCR using the ABI PRISM 7900 (Applied Biosystems, 
Foster City, CA) with TaqMan® Master Mix (Applied Biosystems), and primers and 
probes for IL-4, IL-10, IL-12, IL-18, IFNγ, VEGF-A and 18S ribosome (sequences 
available on request) (Applied Biosystems). Expression of cytokine mRNA in each 
sample was normalized relative to that of 18S ribosome mRNA. 
 
Cytotoxic T lymphocyte assay (51Cr release assay) 
The cytolytic activity of mouse spleen cells was assessed by a 51Cr release 








were harvested aseptically and mashed in alpha-MEM medium (Gibco) with 10 % FBS, 
and suspensions of single spleen cells were prepared. Spleen cells were cultured with 
mitomycin C (MMC; Sigma, ST. Louis, MO) (400 μg/4 ml, 1 mg/ml in HBSS) treated 
BNL or CT26 cells in complete alpha-MEM medium containing 10 % FBS and 2.5 % 
EL-4 culture supernatant (a source of T cell growth factor) for 5 days. Target cells 
consisted of 3 × 105 BNL cells labeled with 0.3 mCi Na251CrO4 (NEN Life Science 
Products, Boston, MA) at 37 °C for 1 hour. Effector spleen cells were incubated with 5 
× 103 target cells in 96-well plates at various effector/target ratios for 4 hours at 37 °C, 
and the 51Cr released into the culture supernatants was quantified by scintillation 
counting. Percent specific cytotoxicity was calculated according to the equation: [100 × 
(experimental release - spontaneous release) / (maximum release - spontaneous release)]. 
Spontaneous release was defined as the 51Cr in the supernatant of target cells incubated 
for 4 hours, and maximum release was defined as 51Cr in the supernatant of target cells 
treated with 2 % Triton-X. Experiments were performed three times and results were 
expressed as the mean ± SE. Tumor specificity was determined based on differences 










CCL2/MCP-1 production of recombinant adenoviruses in vitro 
 The production of CCL2/MCP-1 was evaluated by measuring the 
concentrations in culture media of BNL cells infected with varying MOIs of Ad-MCP1 
and Ad-MCP1 plus Ad-tk by ELISA (Figure 1B). The production of CCL2/MCP-1 by 
cells infected with Ad-MCP1 increased in proportion to the MOI. Importantly, its 
production by Ad-MCP1 infected cells was not changed when these cells were further 
infected with Ad-tk (Ad-MCP1 plus Ad-tk), indicating that CCL2/MCP-1 production by 
Ad-MCP1 was not influenced by coinfection with Ad-tk in BNL cells. In addition, the 
functional properties of CCL2/MCP-1 produced by this rAd were defined previously 
[6-8]. 
 
Intrahepatic tumor development following transfer of HCC cells infected with 
recombinant adenoviruses 
To evaluate the direct antitumor effect of CCL2/MCP-1 in an 
immunocompetent mouse model of IM, mice were injected via the PV with BNL cells 
infected with Ad-MCP1 or Ad-LacZ at various MOIs (Figure 1C). When whole livers 








comparable to those of L (n=4) mice, indicating that delivery of CCL2/MCP-1 gene did 
not promote or suppress the growth of tumor cells in this model. 
To determine whether CCL2/MCP-1 gene delivery can potentiate the antitumor 
effects of the HSV-tk/GCV system, mice were injected with BNL cells infected with 
rAds (Ad-tk, Ad-MCP1 and Ad-LacZ) at various MOIs as described in Materials and 
methods. Whole livers were weighed on day 21, and the weights of T/MLow (n=14), 
T/MMod (n=12), T/MHigh (n=11) and T/L (n=10) mice were compared to those of N/L 
(n=10) mice. The reduction in liver weight for the T/L mice was due to HSV-tk/GCV 
system alone and those for T/MLow, T/MMod and T/MHigh were due to the treatment in 
combination with CCL2/MCP-1. Mean liver weight (± SEM) was significantly lower in 
T/MLow mice than in T/L mice (3.91 ± 0.36 g vs. 5.80 ± 0.58 g ; P < 0.01) (Figure 1D 
and 1E), due to the reduced growth of implanted tumor cells in the former. In contrast, 
the increase in liver weight was not suppressed in T/MMod and T/MHigh mice whose 
tumor cells had been treated with higher titers of Ad-MCP1. Thus, only low level 
CCL2/MCP-1 provided additional antitumor effects and these results indicate that 
delivery of adequate amounts of Ad-MCP1 enhanced the antitumor effects of the 









Serial analysis of liver histology following tumor cell transfer 
To monitor the course of tumor development following HCC cell transfer, 
mouse livers were harvested on days 1, 3, 7 and 14. Livers harvested on day 1 from all 
groups of mice injected with BNL cells showed multiple white patches on their surfaces. 
Histologically, hepatocyte degeneration and necrosis were observed in these lesions, 
suggesting that the reduction of PV flow by transferred tumor cells induced focal 
ischemic necrosis in the livers (Figure 2, closed arrowheads). Although the extent of 
necrosis was similar among all groups, inflammatory cell infiltration in the area of 
necrosis was greater in T/MLow, T/MHigh and T/L than in N/L mice. On day 3, cellular 
infiltration disappeared, and tumor cell growth was observed in areas surrounding the 
necrotic regions. On day 7, proliferation of viable tumor cells surrounding the necrosis 
was seen in the livers of N/L mice, with the necrotic tissues completely replaced by 
tumor cells. Tumor growth was moderately inhibited in T/L mice and greatly inhibited 
in T/MLow mice. There was no difference between T/L and T/MHigh mice (not shown). 
On day 14, the necrotic areas were almost absorbed in all mice. In N/L mice, the tumor 
cells grew progressively and the tumor masses became larger. Tumor volume was 
relatively lower in T/L than in N/L mice, but there was no significant difference 








observed in T/MLow mice (Figure 2). 
 
Recruitment of immune cells in liver 
To evaluate the involvement of immune responses in the CCL2/MCP-1 
associated enhancement of the antitumor effects of rAd expressing HSV-tk, we assessed 
the recruitment of Mac-1+ monocytes/macrophages and CD4+ and CD8+ T lymphocytes 
immunohistochemically (Figure 3).  
T/MLow and T/MHigh mouse liver tissues harvested on day 1 showed marked 
infiltration of Mac-1+ cells in the necrotic areas induced by tumor cell injection (Figure 
3A). Quantitative morphometric analysis showed that the numbers of Mac-1+ cells were 
significantly higher in liver tissues of T/MLow and T/MHigh mice [mean ± SEM of 40 
high power (× 400) fields of necrotic liver tissues: 46.5 ± 3.7 and 46.9 ± 3.7; P < 0.05 
and P < 0.01, respectively] compared with T/L mice [35.2 ± 2.4]. Macrophages can be 
activated not only by CCL2/MCP-1, but also by tumor cells treated with Ad-tk [6]. In 
T/L mice, these cells may induce moderate infiltration of Mac-1+ cells (Figure 3B). 
These findings indicate that the codelivery of the HSV-tk and CCL2/MCP-1 genes was 
associated with a higher degree of infiltration of Mac-1+ monocytes/macrophages 








recruited monocytes/macrophages were polarized towards the M1 or M2 phenotype, we 
performed immunohistochemical analysis using antibodies against iNOS (M1) and 
Arg-I (M2) [17, 18] (Figure 3C). The proportion of iNOS+ (M1 subset) cells among the 
inflammatory cells was significantly higher in T/MLow than in T/MHigh mice [mean 
numbers ± SEM (per 100 inflammatory cells) of eight high power (× 400) fields of 
necrotic liver tissues: 23.0 ± 2.7 and 10.8 ± 2.5; P < 0.01, respectively]. Arg-I+ (M2 
subset) cells were not specifically detected, probably due to large amounts of the 
enzyme present in liver tissues. 
 Similarly, liver tissues obtained on day 14 after HCC cell transfer were 
immunohistochemically analyzed for immune cell infiltration. In both T/MLow and 
T/Mhigh mice, the tumor foci were heavily infiltrated by CD4+ and CD8+ T cells (Figure 
3D). Quantitative morphometric analysis showed that the numbers of CD4+ and CD8+ T 
cells were higher in T/MLow [mean numbers ± SEM (per 100 tumor cells) of eight high 
power (× 400) fields of liver tissues: 11.1 ± 2.5 and 8.1 ± 2.7; P < 0.05 and P < 0.05, 
respectively] and T/MHigh [7.1 ± 1.9 and 7.1 ± 0.7; N.S and P < 0.01, respectively] mice 
than in T/L mice [4.8 ± 1.1 and 0.3 ± 0.3, respectively] (Figure 3E). These results 
suggest that the antitumor activities in T/MLow mice may be mediated not only by the 








the induction of T cell-mediated immune responses during later periods. 
 
Cytokine gene expression in liver 
Mice injected with adenovirus-infected HCC cells were sacrificed on day 1 and 
their liver tissues were analyzed by quantitative real-time RT-PCR for expression of 
mRNA encoding the cytokines IL-4, IL-10, IL-12, IL-18 and IFN-γ. IL-12 mRNA 
expression was induced to a greater extent in T/MLow mice than in the other groups (P < 
0.05). IL-18 mRNA expression tended to be high in the mice treated with CCL2/MCP-1, 
but these differences were not statistically significant (Figure 4). In contrast, IL-4, IL-10 
and IFN-γ mRNA was not detected in any samples. These data suggest that infiltrating 
monocytes/macrophages induced by CCL2/MCP-1 may be activated to enhance the 
Th1-polarized responses that contribute to tumor immunity. 
 
Microvessels in HCC 
 CCL2/MCP-1 has been shown to be associated with angiogenesis [19, 20]. To 
understand the basis of the different antitumor effects observed in T/MLow and T/MHigh 
mice, we immunohistochemically stained microvessels within HCCs for CD31. We 








T/MHigh mice relative to T/MLow and T/L mice (Figure 5A). These results suggest that 
angiogenesis induced by large amounts of CCL2/MCP-1 may contribute to tumor 
growth in T/MHigh mice. 
 
VEGF gene expression in liver 
 Liver samples harvested on day 3 were analyzed for expression of VEGF-A 
mRNA, which encodes an angiogenic factor that may promote tumor growth. 
Quantitative real-time RT-PCR showed that VEGF-A gene expression was induced to a 
greater extent in T/MHigh mice (Figure 5B), suggesting that the CCL2/MCP-1 
enhancement of antitumor effects may be offset by VEGF-induced angiogenesis.   
 
Cytotoxic activities of splenocytes 
To assess the cytotoxic activities of immune cells derived from mice injected 
with adenovirus-infected tumor cells, isolated and pulsed splenocytes were incubated 
with 51Cr-labeled BNL cells in a standard 4-hour cytotoxicity assay (Figure 6). 
Induction of cytotoxic T lymphocytes (CTLs) specific for BNL cells was higher in 
T/MLow and T/MHigh mice than in T/L (N.S.) and N/L (P < 0.01) mice, and there was no 








viral vectors or transgene products is known to induce the unfavorable host immune 
responses, the detection of antitumor CTL activities may be influenced by the responses 
against rAd vector and HSV-tk [21-23]. Especially, CTL responses against HSV-tk seem 
to be induced in T/L, T/MLow and T/MHigh mice. Collectively, the data suggest that 
cytotoxic activity of CTLs may be enhanced by codelivery of a suicide gene and 










We have shown here that combination gene therapy, using the HSV-tk/GCV 
system and CCL2/MCP-1 gene delivery, was effective for the treatment of HCC in a 
mouse model of IM. Delivery of an adequate amount of CCL2/MCP-1 enhanced the 
antitumor effects of the HSV-tk/GCV system against intrahepatic tumor cells. Necrotic 
areas induced by HCC tumor cell injection showed marked infiltration of iNOS+ 
monocytes/macrophages and IL-12 production on day 1, and the tumor foci showed 
heavy infiltration by CD4+ and CD8+ T cells on day 14. CTLs specific for BNL cells 
were induced in mice treated with CCL2/MCP-1. In contrast, expression of the 
angiogenic factor VEGF-A was significantly increased in mice treated with a large 
amount of CCL2/MCP-1. Collectively, these results suggest that delivery of an adequate 
amount of CCL2/MCP-1, in conjunction with the HSV-tk/GCV system, may display 
beneficial antitumor effects, preventing the intrahepatic metastasis of HCC cells. 
In the development of this model, we injected 1 × 106 of tumor cells infected 
with recombinant adenoviruses into the portal vein because the injection of fewer cells, 
e.g. 105, resulted in much diminished frequencies of metastasis in the mice. The 








aggregates in the portal vein, which may have contributed to the induction of ischemic 
necrosis in the liver tissues. The resultant ischemic death of liver cells may be 
recognized by immune cells including macrophages and may result in macrophage 
activation and the local release of cytokines and chemokines. However, when the mice 
were injected with control tumor cells (N/L), we observed little infiltration of immune 
cells, including macrophages and CD4+ and CD8+ T cells, and these mice developed 
the largest amounts of tumor tissues. These results indicate that any unfavorable effects 
due to ischemic cell death were minimal for the development of intrahepatic metastasis 
in this model. 
 This model would be more relevant if ganciclovir treatment was delayed, to 
allow establishment of tumors. Therefore, we performed the additional experiments 
with ganciclovir treatment at delayed time point, day 3. While there was a trend for 
small amount of MCP-1 to enhance the antitumor effects of the HSV-tk/GCV system as 
seen in the experiments on day 1, these differences did not reach statistical significance; 
T/MLow: 7.64 ± 1.25 (n = 10), T/MMod: 9.24 ± 0.77 (n = 5), T/MHigh: 9.65 ± 1.06 (n = 8), 
T/L: 10.51 ± 1.79 (n = 7) and N/L: 13.94 ± 1.16 (n = 5). Consequently, the experiment 
in which ganciclovir was added 3 days after tumor inoculation failed to show a 








the tumor model. The reason is that MCP-1 gene expression by rAds may not be enough 
to enhance antitumor effect at day 3 because the transgene expression gradually 
diminished with the tumor growth. In our previous studies, MCP-1 production reached 
peak level on day 2 and decreased after day 3 [6]. 
 
Mice treated with small amounts of CCL2/MCP-1 showed enhancement of 
antitumor effects. The amount of CCL2/MCP-1 delivered, however, was not correlated 
with monocyte/macrophage accumulation. Although activated monocytes/macrophages 
are indicative of the potential to eliminate tumor cells [24-26], infiltrating macrophages 
may enhance tumor growth by secreting growth and angiogenic factors, including 
VEGF [26-28]. Immunohistochemical analysis of CD31 revealed that microvessels in 
HCCs were increased in the mice treated with large amounts of CCL2/MCP-1. We also 
observed a close correlation between the amounts of CCL2/MCP-1 delivered and the 
levels of VEGF expression. These findings suggest that large amounts of CCL2/MCP-1 
may recruit macrophages to induce tumor cell killing and simultaneously to facilitate 
tumor growth, probably by promoting angiogenesis, thus resulting in a reduction of 
antitumor effects.  








migration of macrophages/monocytes, T lymphocytes, natural killer cells and natural 
killer T cells, not only to sites of inflammation but also to tumor tissues, which may 
contribute to the inhibition of tumor growth [29-31]. In addition, the production of 
CCL2/MCP-1 by tumor tissues has been reported to be associated with favorable 
prognoses in human pancreatic cancer [31] and neuroblastoma [30]. In contrast, 
CCL2/MCP-1 may promote tumor growth by chemoattracting tumor-associated 
macrophages for tumor angiogenesis, or by acting on tumor cells as an autocrine growth 
factor[29, 32, 33]. Consistent with this notion, a Japanese study of 135 breast cancer 
patients found that the women with high levels of tumor-associated CCL2/MCP-1 
showed a significantly shorter relapse-free survival [34]. Taken together, the biological 
and immunological effects of CCL2/MCP-1 seem to vary greatly depending on the 
diverse microenvironments of cancer tissues. 
Two major types of activated macrophages have been described, M1 (classical) 
and M2 (alternative) [35-38]. M1 macrophages, which play a critical role in the 
development of antitumor immunity, are characterized by high IL-12 and low IL-10 
production. In contrast, M2 macrophages produce reduced amounts of IL-12 but higher 
levels of IL-10. We found that IL-12 expression was significantly increased in mice 








amount of CCL2/MCP-1, despite the marked infiltration of monocytes/macrophages in 
the latter. In addition, members of the MCP family have been reported to 
dose-dependently inhibit IL-12 production by antigen-presenting cells (APCs) [39, 40]. 
Because of the different local concentrations of CCL/MCP-1, we hypothesized that the 
M1/M2 ratio of recruited monocytes/macrophages may differ in T/MLow and T/MHigh 
mice. Indeed, we found that the proportions of M1 cells among infiltrating cells were 
significantly higher in T/MLow than in T/MHigh mice. Therefore, M1 
monocyte/macrophage polarization may be suppressed in mice treated with large 
amounts of CCL2/MCP-1, resulting in the reduction of antitumor immunity and the 
promotion of tumor growth. 
Significant tumor infiltration of CD4+ and CD8+ T cells 14 days after transfer 
was observed in mice treated with the HSV-tk/GCV system plus CCL2/MCP-1. Local 
secretion of CCL2/MCP-1 by tumor cells may lead to the recruitment and activation of 
antigen-presenting monocytes/macrophages [41, 42]. Once attracted to the tumor tissues, 
these APCs may ingest pathogenic antigens and transport them to local lymphoid organs, 
where the antigens are presented to naive T cells, thus establishing a T cell-mediated 
antitumor response [43]. Tumor growth may thus be impeded by tumor antigen-specific 








 Although the data presented here appear promising, several problems remain to 
be solved before clinical application. Our liver metastasis model using a mouse HCC 
cell line may not be comparable to intrahepatic metastasis of HCC in human patients. 
However, HCC patients treated by nonsurgical procedures, including percutaneous 
radiofrequency ablation therapy and transcatheter arterial chemotherapy [44, 45], could 
also be administered rAds to reduce the incidence of intrahepatic recurrence and 
metastasis. Our study demonstrated that, in a mouse model, there is a negative impact 
on tumor development in the presence of a low level of CCL2/MCP-1 whereas high 
levels of the protein complicate the situation by having a positive impact on tumor 
growth, i.e. a balance is required. The therapeutic effects may vary with different tumors. 
 The direct correlation between overexpression of VEGF in tumor cells and 
tumor angiogenesis has been demonstrated [46], and large amount of CCL2/MCP-1 
might be less effective in the treatment of hypervascular tumors such as HCC. However, 
other cancers resistant to anti-angiogenic drug, e.g. pancreatic cancer [47, 48], probably 
don’t need a good blood supply for tumor growth. In treatment of hypovascular tumors 
which are resistant to anti-angiogenic drug, CCL2/MCP-1 may enhance the antitumor 
effects via activation of M1 macrophages. 








experiments of the vectors to existing tumors. There would be many complicated factors 
to affect the delivery of HSV-tk and CCL2/MCP-1 genes in therapeutic approaches [49, 
50]. Intra-arterial administration of rAds may result in the induction of immunogenicity 
or cytotoxicity, especially when spread via blood flow. Extremely high-dose rAds have 
been found to cause severe unexpected side effects [51]. To overcome these problems, 
highly tumor-specific promoters may be needed. In our previous studies, human 
alpha-fetoprotein (AFP) promoters specific for liver cancer cells were used in an 
immunodeficient nude mouse models [6, 52]. A reporter gene was specifically 
expressed in AFP producing tumors which were xenografted subcutaneously and 
disseminated in the liver and lung. However, HSV-tk gene expression was not enhanced 
enough to kill established tumor cells [53] because the transcriptional activity of AFP 
promoter was relatively low. Furthermore, neither promoters nor delivery systems were 
found to be specific for the BNL mouse tumor cell line. Although better methods of 
tumor-specific gene delivery and expression are needed, the use of ex vivo infection 












 Although problems with rAds remain to be resolved prior to clinical 
application, our results suggest that a new strategy, consisting of immune gene therapy 
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Figure 1. Chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-1) 
production and antitumor effects of recombinant adenovirus vectors (rAds). A; 
Schematic representation of rAds expressing each gene under the control of a CAG 
promoter. (a) Ad-MCP1 expressing CCL2/MCP-1, (b) Ad-tk expressing HSV-tk, (c) 
Ad-LacZ expressing beta-galactosidase gene (LacZ). Solid lines indicate the rAd 
genome, and the open triangle below each rAd genome represents deletions of 
adenovirus early regions. The arrow shows the orientation of transcription. GpA, rabbit 
beta-globin (A) site; CAG, CAG promoter. B; Production of CCL2/MCP-1 by BNL 
cells infected with rAds at various multiplicity of infections (MOIs). The CCL2/MCP-1 
concentrations in culture supernatants were determined by ELISA. Data shown are the 
means of three independent results with standard error bars. C; Liver weight following 
transfer of BNL cells infected with Ad-MCP1, Ad-LacZ or PBS (-). Each mouse was 
injected via the portal vein (PV) with 1 × 106 BNL cells infected with Ad-MCP1 at 
various MOIs: 0.03 (MLow), 0.3 (MMod), and 3 (MHigh), and Ad-LacZ at the MOI of 3 (L), 
and the whole livers were weighed on day 21. D; CCL2/MCP-1 enhancement of the 








mouse was injected via portal vein with BNL cells (1 × 106) infected with Ad-tk, 
Ad-MCP1 and Ad-LacZ at various MOIs, Ad-tk/Ad-MCP1 = 3/0.03 (T/MLow), 3/0.3 
(T/MMod) and 3/3 (T/MHigh), Ad-tk/Ad-LacZ = 3/3 (T/L), and Ad-LacZ = 6 (N/L), and 
the whole livers were weighed on day 21. E; The macroscopic views of hepatic tumors 
(open arrowheads) in mice. Tumor growth was markedly suppressed in T/MLow mice. 
The bars equal 10 mm.  
 
Figure 2. Serial analysis of liver histology following tumor cell transfer. Mouse liver 
tissues were harvested on days 1, 3, 7 and 14, and stained with hematoxylin and eosin 
(H-E). On day 1, all mice injected with BNL cells showed multiple white patches on the 
liver surface (not shown). Histologically, hepatocyte degeneration and necrosis were 
observed in these lesions, suggesting that the reduction of PV flow by transferred tumor 
cells induced focal ischemic necrosis in the livers. The area of necrosis significantly 
infiltrated with inflammatory cells (closed arrowheads) was higher in T/MLow, T/MHigh 
and T/L mice than in N/L mice. On day 3, cellular infiltration disappeared and tumor 
cell growth (closed arrows) was detected in areas surrounding the necrotic regions. On 
day 7, tumor tissue enlarged and replaced the necrotic areas (open arrows). On day 14, 








Original magnifications × 40 and × 200． 
 
Figure 3. Immunohistochemical evaluation of monocyte/macrophage (A-C) and T cell 
(D and E) recruitment into liver tissues. A; Monocyte/macrophage detection using 
anti-Mac-1 monoclonal antibody. Original magnification × 400. B; Quantitative 
morphometric analysis of Mac-1+ cells. C; Immunohistochemical evaluation of the 
polarization towards M1 phenotype of recruited monocytes/macrophages using 
antibody against inducible nitric oxide synthase (iNOS) (closed arrowheads). D; CD4+ 
(closed arrows) and CD8+ (open arrows) T cell detection. Original magnification × 400. 
E; Quantitative morphometric analysis of CD4+ and CD8+ T cells. 
 
Figure 4. Real-time quantitative RT-PCR for IL-12 and IL-18 mRNA expressions in 
liver on day 1. IL-12 gene expression was significantly higher in T/MLow mice than in 
the other groups (P < 0.05). 
 
Figure 5. Evaluation of tumor angiogenesis. A; Morphometric analysis of microvessels 
in tumor tissues using H-E staining and CD31 immunohistochemical analysis. (a) 








intratumoral microvessels containing red blood cells (closed arrow); endothelial cells 
were not identified. (b) Representative CD31 immunohistochemical staining showing 
endothelial cell proliferation in tumor tissues (open arrow). Original magnification × 
400. B; Real-time quantitative RT-PCR for VEGF-A mRNA expression in liver on day 
3. 
 
Figure 6. Cytotoxic activities of splenocytes. Splenocytes harvested on day 14 from 
individual mice stimulated with MMC-treated BNL cells for 7 days were tested in a 
standard 4h cytotoxicity assay with 51Cr-labeled target (BNL) or control (CT26) cells. 
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